Health Care Service Corp. v. TAP Pharmaceutical Products, Inc.

274 F. Supp. 2d 807, 30 Employee Benefits Cas. (BNA) 2891, 2003 U.S. Dist. LEXIS 13556, 2003 WL 21801636
CourtDistrict Court, E.D. Texas
DecidedAugust 1, 2003
Docket9:03-cv-00166
StatusPublished
Cited by5 cases

This text of 274 F. Supp. 2d 807 (Health Care Service Corp. v. TAP Pharmaceutical Products, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Health Care Service Corp. v. TAP Pharmaceutical Products, Inc., 274 F. Supp. 2d 807, 30 Employee Benefits Cas. (BNA) 2891, 2003 U.S. Dist. LEXIS 13556, 2003 WL 21801636 (E.D. Tex. 2003).

Opinion

MEMORANDUM OPINION AND ORDER

RON CLARK, District Judge.

HCSC, an administrator of employer sponsored benefits plans, has moved to remand a suit in which it claimed defendant drug companies engaged in a pattern of overcharging for, and encouraging the over-prescription of, Lupron, a prostate drug [Doc. # 6]. This court must reject HCSC’s claim that even though it is a plan administrator, it is not an ERISA fiduciary. If HCSC’s allegations are correct, defendants are deemed to be fiduciaries of the plans from which they improperly obtained funds and are equitably required to disgorge these funds. Accordingly, this is a case of complete preemption of a suit to obtain equitable redress for an alleged prohibited practice under ERISA.

Additionally, if HCSC’s allegations are true, potentially millions of dollars of overcharges on this single drug have been mulcted from plans paid for by employers, and intended to benefit hardworking employees and their dependents. The national policy implications for employees, employers, and benefit plans are multiplied if similar activity has occurred with other medications. No one can deny that protection of plan assets for the benefit of participants and beneficiaries was a central goal of Congress in enacting ERISA. HCSC’s action for restitution due to defendants’ unjust enrichment is governed by federal common law, and it “arises under” federal law for purposes of maintaining subject matter jurisdiction in this court. HCSC’s motion to remand is denied.

I. FACTUAL AND PROCEDURAL BACKGROUND

On July 12, 2002, HCSC filed its Plea in Intervention (hereinafter referred to as HCSC’s “Complaint”) in a state court class action in which individuals were suing defendants TAP, Abbott and Takeda Chemical Industries (“Takeda”) for allegedly promoting unnecessary prescriptions, and overcharging for a drug called Lupron. HCSC alleged that through its divisions (various Blue Cross and Blue Shield organizations), it was the third-party payor of many of the alleged unnecessary or inflated charges for Lupron.

On that same day, the State District Court severed HCSC’s claims, resulting in a new action with HCSC as the only plaintiff, and TAP, Abbott, and Takeda as defendants. HCSC alleges state law claims of civil conspiracy, violation of the Illinois Consumer Fraud and Deceptive Business Practices Act, unjust enrichment, fraud, and violation of the Illinois Antitrust Act. Six months after HCSC filed its Complaint, and four months after defendants had answered, TAP served HCSC with discovery. The response to the discovery was received by defendants on February 18, 2003. Defendants filed their Notice of Removal [Doc. # 1] on March 20, 2003. HCSC has moved to remand asserting federal preemption does not apply and that the notice of removal was filed too late.

II. PREEMPTION OF STATE LAW CLAIMS

Although HCSC’s Complaint purported to raise only state law causes of action, *811 defendants removed this case by invoking federal jurisdiction under the Employee Retirement Income Security Act of 1974 (“ERISA”), §§ 502, 514, 29 U.S.C. §§ 1132, 1144. 1 An action filed in state court may be removed to federal court if the claim is one “arising under” federal law. See 28 U.S.C. § 1441(b).

Under the well-pleaded complaint rule, a case does not “arise under” federal law and is not removable if the complaint asserts only state law causes of action. Franchise Tax Bd. v. Constr. Laborers Vacation Trust, 463 U.S. 1, 10, 103 S.Ct. 2841, 77 L.Ed.2d 420 (1983). An anticipated federal defense, including a defense of preemption, will not support removal either. Caterpillar Inc. v. Williams, 482 U.S. 386, 393, 107 S.Ct. 2425, 96 L.Ed.2d 318 (1987).

A. Claims Under ERISA 29 U.S.C. § 1132(a) Are Preempted

State law claims that seek relief within the scope of the civil enforcement provisions of ERISA § 502(a), 29 U.S.C. § 1132(a), can be characterized as claims arising under federal law. See Metro. Life Ins. Co. v. Taylor, 481 U.S. 58, 64-66, 107 S.Ct. 1542, 95 L.Ed.2d 55 (1987). A federal court has “complete preemption” jurisdiction over such claims, and the action can properly be removed to federal court. 2 Arana v. Ochsner Health Plan, 338 F.3d 433 (5th Cir.2003)(citing Metro. Life Ins. Co. v. Taylor, 481 U.S. at 66).

ERISA § 502(a)(3), 29 U.S.C.

§ 1132(a)(3), provides:

A civil action may be brought—
* * *
(3) by a ... fiduciary ... (A) to enjoin any act or practice which violates any provision of [ERISA] or the terms of the plan, or (B) to obtain other appropriate equitable relief (i) to redress such violations or (ii) to enforce any provisions of [ERISA] or the terms of the plan.... (Emphasis added).

As will be discussed, HCSC, as a plan administrator, is a fiduciary. This suit seeks to obtain equitable relief to redress violations of the “prohibited transactions” provisions of ERISA, 29 U.S.C. § 1106. The claims are therefore within the scope of 29 U.S.C. § 1132 and complete preemption jurisdiction applies.

1. HCSC is an ERISA Fiduciary

The court must determine the status, under ERISA, of HCSC and defendants to determine whether the action brought is, in reality, one to redress violations of ERISA, or to enforce any provisions of ERISA. If HCSC is a fiduciary, and its suit redresses transactions prohibited by ERISA, then this is a case arising under Federal law and removal was proper.

ERISA § 3(21)(A), 29 U.S.C. § 1002(21)(A), defines a fiduciary as follows:

[A] person is a fiduciary with respect to a plan to the extent (i) he exercises *812 any discretionary authority or discretionary control respecting management of such plan or exercises any authority or control respecting management or disposition of its assets, ...

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Blue Cross of Cal. Inc. v. Insys Therapeutics Inc.
390 F. Supp. 3d 996 (D. Arizona, 2019)
JHohman, LLC v. United States Security Associates, Inc.
513 F. Supp. 2d 913 (E.D. Michigan, 2007)
Smith v. Metropolitan Life Insurance
344 F. Supp. 2d 696 (D. Colorado, 2004)
Thompson v. Abbott Laboratories
309 F. Supp. 2d 165 (D. Massachusetts, 2004)
In Re Pharmaceutical Industry Average Wholesale Price Litigation
309 F. Supp. 2d 165 (D. Massachusetts, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
274 F. Supp. 2d 807, 30 Employee Benefits Cas. (BNA) 2891, 2003 U.S. Dist. LEXIS 13556, 2003 WL 21801636, Counsel Stack Legal Research, https://law.counselstack.com/opinion/health-care-service-corp-v-tap-pharmaceutical-products-inc-txed-2003.